Effect of Fascioliasis on the pharmacokinetic parameters of triclabendazole in human subjects
- 161 Downloads
To study the clinical efficacy of Triclabendazole (TCBZ) on Egyptian patients infected with Fasciola and understand the effect of Fascioliasis on the pharmacokinetics of TCBZ.
The pharmacokinetics of TCBZ administered as a single oral dose (10 mg/kg) was investigated in both infected and parasite––free Egyptian subjects. After oral administration, TCBZ is metabolized to a sulphone and sulfoxide derivatives. The latter is responsible for the fasciolicidal activity of TCBZ, and it could be used as a marker of drug bioavailability. Blood samples were collected following the oral administration, and TCBZ sulfoxide plasma concentrations were determined by a sensitive and specific HPLC method.
Pharmacokinetic parameters (C max, AUC0–48, t 1/2 and t max) for TCBZ sulfoxide were calculated. In patients; the mean C max was 9.11 ± 1.3 μg/ml, the mean AUC (0–48) was 91 ± 10.5 μg h ml−1, the mean t 1/2 was 7.4 ± 0.6 h, and the t max was 3.0 ± 0.4 h. In normal subjects, the mean C max was 8.48 ± 0.92 μg/ml, the mean AUC(0–48) was 85 ± 6.55 μg h ml−1, the mean t 1/2 was 6.2 ± 0.357 h, and the t max was 3 ± 0.4 h. No significant difference could be detected in the patients as compared to normal subjects, which would suggest that Fascioliasis does not affect any of the studied parameters.
No eggs in faeces could be detected following TCBZ treatment. Also, most of the clinical investigations showed significant decline back to the normal ranges post-treatment which indicates complete curing and high TCBZ efficacy.
Fasioliasis as an infective condition widely spread in Egypt has no significant effect on the pharmacokinetic parameters of the orally administered TCBZ and at the same time it is very effective against the parasite which strongly and safely suggests the use of this medication for the treatment of this infection.
KeywordsTriclabendazole sulfoxide Clinical investigation Eggs Pharmacokinetics Fascioliasis
The authors are thankful to Prof. Dr. Salah El-Banawy, Internal Medicine Department, Medical Research Institute, Alexandria for his medical supervision during the period of this self funded study.
- 1.Laburte C, Mott KE, Hull R, Severne Y. Triclabendazole for fascioliasis: efficacy and tolerability of a single treatment. Infectious diseases and public health. A research and clinical update. In: Angelico M, Rocchi G, editors. Italy: Balaban Publishers; p. 325–333.Google Scholar
- 6.Robert W, Tolan RW Fascioliasis, http://www.emedicine.com/ped/topic760.htm. Cited 14-5-2006 Google Scholar
- 11.Sanyal PK Pharmacokinetic behaviour of triclabendazole in domestic Ruminants follows single and divided dose administration. J Vet Parasitol 1998; 12(2):89–93.Google Scholar
- 18.Lancaster R 1980 Pharmacology in clinical practice. Butterworth – Williams Heinenmann Medical books Ltd, London (UK), p. 44. ISBN 0433190523.Google Scholar
- 19.Chen MG, Mott KE Progress in assessment of morbidity due to Fasciola Hepatica infection: a review of recent literature. Trop Dis Bull 1990; 87:1–26.Google Scholar
- 21.Yadegari D, Talaie H, Massoud J Clinical trial of triclabendazole on human fascioliasis: long term follow-up. Med J Islam Rep Iran 1999; 13:89–91.Google Scholar